Pulse Biosciences, Inc. reported on April 25, 2026, that their nPulse Cardiac Catheter System achieved a 100% procedural success rate at 6 months and 96% at one year in a pivotal study presented at Heart Rhythm 2026. The study also detailed low serious adverse events at 1.7% among 177 subjects, indicating a strong safety profile.